Minims Oxybuprocaïnehydrochloride Bausch + Lomb Ireland Limited (Oxybuprocaine Hydrochloride)

Oxybuprocaine hydrochloride blocks voltage‑gated sodium channels on peripheral nerve endings in the cornea and conjunctiva. By preventing sodium influx, it stops the generation and propagation of nerve impulses, resulting in rapid, reversible anesthesia of the ocular surface without affecting deeper ocular structures.

The specific dosing regimen for Minims Oxybuprocaine is determined by the prescribing clinician based on the procedure, patient age, and clinical setting. Healthcare professionals select the appropriate number of drops and frequency according to established ophthalmic guidelines.

Safety data for oxybuprocaine hydrochloride in pregnancy and lactation are limited. It should only be used when clearly needed after a careful risk‑benefit assessment by the treating physician, and alternative options should be considered whenever possible.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Oxybuprocaine is an ester‑type local anesthetic offering rapid onset and short duration of action, similar to proparacaine and tetracaine. Compared with amide‑type agents, it may have a slightly higher risk of corneal toxicity with repeated use, but it provides reliable anesthesia for brief diagnostic and minor surgical procedures.

The product should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect it from direct sunlight, moisture and extreme temperature fluctuations to maintain sterility and potency.

Minims Oxybuprocaine is administered as an ophthalmic drop. The prescribed number of drops is placed onto the conjunctival sac, typically one drop per eye, allowing the solution to spread over the corneal surface. The patient should keep the eye closed briefly to enhance absorption.

Serious risks, though rare, include corneal epithelial toxicity, persistent ulceration, severe allergic reactions such as anaphylaxis, and significant increases in intra‑ocular pressure. Prompt medical attention is required if any signs of severe irritation, vision loss, or systemic allergic response occur.

Patients with known hypersensitivity to oxybuprocaine, other ester‑type anesthetics, or any component of the formulation should avoid its use. It is also contraindicated in eyes with active corneal infection, severe epithelial defects, or in individuals where the risk of corneal toxicity outweighs the benefit.